Menta Capital LLC Takes Position in Amneal Pharmaceuticals Inc (AMRX)

Share on StockTwits

Menta Capital LLC acquired a new stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 29,756 shares of the company’s stock, valued at approximately $403,000.

Several other large investors also recently made changes to their positions in the stock. RMB Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 29.3% in the fourth quarter. RMB Capital Management LLC now owns 61,759 shares of the company’s stock valued at $836,000 after acquiring an additional 13,988 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 889,980 shares of the company’s stock valued at $12,041,000 after acquiring an additional 108,455 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Amneal Pharmaceuticals by 30.4% in the fourth quarter. Stifel Financial Corp now owns 578,967 shares of the company’s stock valued at $7,807,000 after acquiring an additional 134,910 shares in the last quarter. Gideon Capital Advisors Inc. lifted its position in shares of Amneal Pharmaceuticals by 46.7% in the fourth quarter. Gideon Capital Advisors Inc. now owns 15,741 shares of the company’s stock valued at $213,000 after acquiring an additional 5,014 shares in the last quarter. Finally, United Services Automobile Association lifted its position in shares of Amneal Pharmaceuticals by 88.6% in the fourth quarter. United Services Automobile Association now owns 103,615 shares of the company’s stock valued at $1,402,000 after acquiring an additional 48,662 shares in the last quarter. Institutional investors own 38.47% of the company’s stock.

In other Amneal Pharmaceuticals news, Director Peter R. Terreri sold 23,345 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $12.39, for a total value of $289,244.55. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Paul Bisaro bought 17,000 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, March 12th. The stock was acquired at an average price of $11.97 per share, for a total transaction of $203,490.00. The disclosure for this purchase can be found here. Company insiders own 3.20% of the company’s stock.

Shares of Amneal Pharmaceuticals stock opened at $13.94 on Monday. Amneal Pharmaceuticals Inc has a one year low of $11.63 and a one year high of $24.48. The company has a market cap of $4.16 billion, a P/E ratio of 22.13, a P/E/G ratio of 0.56 and a beta of 1.37. The company has a current ratio of 2.32, a quick ratio of 1.50 and a debt-to-equity ratio of 2.98.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings data on Thursday, February 28th. The company reported $0.33 EPS for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.06. Amneal Pharmaceuticals had a return on equity of 25.73% and a net margin of 1.84%. On average, research analysts predict that Amneal Pharmaceuticals Inc will post 0.9 earnings per share for the current year.

Several equities analysts have recently weighed in on AMRX shares. Svb Leerink downgraded Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $16.00 to $12.00 in a research report on Friday, March 8th. Leerink Swann restated an “outperform” rating and issued a $19.00 target price (down previously from $25.00) on shares of Amneal Pharmaceuticals in a research report on Thursday, January 3rd. Morgan Stanley downgraded Amneal Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $24.00 to $18.00 in a research report on Friday, December 14th. Cantor Fitzgerald restated a “buy” rating and issued a $35.00 target price on shares of Amneal Pharmaceuticals in a research report on Thursday, February 28th. Finally, Zacks Investment Research downgraded Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $20.70.

ILLEGAL ACTIVITY NOTICE: “Menta Capital LLC Takes Position in Amneal Pharmaceuticals Inc (AMRX)” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://weekherald.com/2019/03/18/menta-capital-llc-takes-position-in-amneal-pharmaceuticals-inc-amrx.html.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

See Also: Buyback

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.